Abbott Laboratories Stock Performance
Abbott Laboratories shares traded at $103.73, reflecting a modest daily gain of 0.47% per SID market data. The stock has experienced notable short-term weakness, declining 9.78% over the past month, though it has posted a solid 17.25% gain over the trailing three-month period. On a one-year basis, ABT has declined 19.84%, underperforming the broader healthcare sector. The stock currently trades below its 50-day moving average of $106.20 but remains slightly above its 200-day moving average of $102.88, according to SID market data. The 14-day relative strength index sits at 25.2, placing the stock firmly in oversold territory and suggesting recent selling pressure has been significant. ABT carries a beta of 0.751, indicating lower volatility relative to the broader market. Average daily trading volume stands at approximately 8.88 million shares, supporting adequate liquidity for institutional participation.
Abbott Laboratories Valuation Analysis
Abbott Laboratories carries a market capitalization of approximately $202.5 billion, positioning it among the largest companies in the healthcare sector, per SID market data. The stock trades at a price-to-earnings ratio of 31.15, reflecting a premium valuation relative to the broader market, though not uncommon for diversified medical device and diagnostics companies. The price-to-book ratio stands at 3.90 according to SEC filings, indicating investors are paying nearly four times book value per share. Notably, the PEG ratio is negative at -0.58, which warrants attention as it may reflect declining forward earnings growth expectations or unusual estimation dynamics. Abbott currently offers a dividend yield of 2.06%, providing income-oriented investors with a meaningful return component. The company's healthcare sector classification and diversified revenue streams across diagnostics, medical devices, nutrition, and pharmaceuticals contribute to the premium valuation multiple the market assigns to its earnings.
Smart Money Activity for ABT
Abbott Laboratories registers a smart money score of 44 out of 100 with a neutral overall signal, per SID market data. The institutional component scores a perfect 25 out of 25, indicating robust conviction and positioning among major institutional holders as reflected in 13F institutional filings. In contrast, the insider activity score sits at 9.7 out of 25, with 14 insider transactions recorded over the past 90 days according to SEC Form 4 filings. These transactions were evenly split between 7 insider buys and 7 insider sells, suggesting no clear directional bias from corporate insiders. The dark pool activity score of 8.5 out of 25 indicates moderate but not elevated off-exchange trading interest. Congressional trading activity remains minimal at just 0.8 out of 25. The divergence between strong institutional confidence and mixed insider sentiment creates a nuanced picture. The balanced insider buying and selling pattern, combined with the high institutional score, suggests that large-scale professional investors maintain strong positions while company executives engage in routine portfolio management.
Abbott Laboratories Earnings Outlook
Abbott Laboratories has demonstrated consistent earnings execution in its most recent reporting periods. In the quarter reported on April 16, 2026, the company posted earnings per share of $1.15, narrowly surpassing the consensus estimate of $1.14 by $0.01, according to company earnings reports. The subsequent quarter reported on July 16, 2026, showed further improvement with actual EPS of $1.31 versus the $1.28 estimate, delivering a $0.03 positive surprise. This sequential EPS growth from $1.15 to $1.31 represents a 13.9% quarter-over-quarter increase. Looking ahead, analyst estimates project EPS of $1.15 for the period with results expected April 15, 2026, and $1.42 for the October 14, 2026 reporting date, per analyst estimates. The $1.42 estimate for the upcoming October quarter would represent the highest projected quarterly EPS figure among tracked periods, suggesting analysts anticipate continued earnings momentum through the second half of the fiscal year.
Wall Street Analyst Ratings for ABT
Wall Street analyst sentiment toward Abbott Laboratories remains decisively bullish, with all five most recent ratings reflecting positive stances, per Wall Street analyst reports. TD Cowen has been the most active coverage firm, reiterating its Buy rating on three separate occasions — September 8, August 25, and July 17, 2026 — demonstrating sustained conviction in the stock. UBS maintained its Buy rating on July 28, 2026, adding to the bullish consensus. The most notable recent action came from Wolfe Research on August 13, 2026, which upgraded ABT from Peer Perform to Outperform, representing the only rating change among tracked analysts. This upgrade is particularly significant given it occurred after the company's earnings beat in the July reporting period. According to SID consensus data, the absence of any Hold, Underperform, or Sell ratings among recent analyst actions indicates broad agreement on Abbott's fundamental trajectory. The stock's current oversold RSI reading of 25.2 may present a disconnect between analyst optimism and recent price action.
